Clinical Trials Clinical Research Therapeutics Regulatory Affairs Regulatory Approval FDA Approval Biotechnology Weight-loss Drugs Pharmaceutical Research Oncology Disease Treatment FDA Regulations Biologics Therapeutic Research Stelara Loss of Exclusivity Mifepristone Ruling Alzheimer's Disease Intellectual Property Scientific Research Tyrosine Kinase Inhibitors Pharmaceuticals Combination Therapy GLP-1 Drugs Innovative Therapies Therapeutic Segments Preclinical Research Efficacy Studies Subcutaneous Administration Experimental Treatments Biosimilars Safety and Efficacy Research Studies Alzheimer's Phase 2 Trials Breakthrough Therapy Designation Phase 3 Trials AI in Healthcare Gene Therapy RNA-based Therapeutics Therapeutic Targets Drug Testing Research Applications Compounding Pharmacies Injectable Medications
The filing sets a May 5 deadline for investors to seek a lead role in a case over alleged misstatements about a Phase 2b alopecia study.
